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Objectives. This study sought to evaluate a biochemical ap-
proach to the early noninvasive assessment of reperfusion.
Background. In patients with an acute myocardial infarction, a
rapid noninvasive method of detecting failure of intravenous
thrombolytic therapy to restore early Thrombolysis in Myocardial
Infarction (TIMI) grade 3 flow in the infarct-related artery (IRA)
is needed.
Methods. Serial blood samples were collected to assay creatine
kinase-MB fraction (CKMB mass), cardiac troponin T and myo-
globin concentrations in 105 patients with a myocardial infarction
who underwent early angiography after intravenous streptoki-
nase. The ratios of the 60- and 90-min concentrations to pre-
thrombolytic values were used to determine an index that could
identify failure to achieve TIMI grade 3 flow in the IRA at 90 min.
Results. Significant increases in serum concentrations of mark-
ers at 60 min were more likely with TIMI grade 3 flow (59
patients) than with TIMI grade 0 to 2 flow (46 patients). Ratios
<25 at 60 min after thrombolysis detected failure to achieve 90-min
TIMI grade 3 flow with 92% to 97% sensitivity, 43% to 60%
specificity and 63% to 76% positive and 86% to 94% negative
predictive values. Ratios <210 at 90 min showed 88% to 95%
sensitivity, 49% to 65% specificity and 61% to 69% positive and
86% to 94% negative predictive values for TIMI flow grade <3.
The overall predictive values were thus similar for all three
markers.
Conclusions. In acute myocardial infarction treated with intra-
venous streptokinase, a simple measurement of increased serum
concentrations of CKMB mass, cardiac troponin T or myoglobin
at 60 and 90 min can accurately predict failure to achieve TIMI
grade 3 flow in the IRA at 90 min.
(J Am Coll Cardiol 1998;31:1499–505)
©1998 by the American College of Cardiology
Intravenous thrombolytic therapy for acute myocardial infarc-
tion (MI) yields maximal benefit if there is early and sustained
restoration of Thrombolysis in Myocardial Infarction (TIMI)
grade 3 flow (1) in the infarct-related artery (IRA) (2).
However, failure of complete reperfusion by 90 min after
thrombolytic administration has been demonstrated (3) in 46%
of patients treated with the best of the current thrombolytic
regimens. Because clinical assessment of thrombolytic efficacy
is unreliable (4,5), a rapid noninvasive method of detecting
failure of complete reperfusion of the IRA could be of
considerable assistance, by identifying the patients who might
benefit from further reperfusion strategies, such as rescue
angioplasty (6).
Because the kinetics of release and clearance of the con-
ventional biochemical markers of myocardial necrosis are not
sufficiently sensitive to monitor reperfusion within the first 60
to 90 min noninvasively, attempts have been made to improve
their sensitivity and specificity by means of multiple samples
and the construction of time–activity curves (7–15). These
methods are complex and time consuming. The use of newer
serum markers of myocyte necrosis, such as myoglobin (16)
and cardiac troponin T (17), could simplify the task. Levels of
these proteins rise rapidly in the serum after successful reper-
fusion therapy of MI (18–22). An analysis based on their early
and rapid rate of release into the bloodstream if TIMI grade 3
flow is restored to the IRA may allow noninvasive assessment
of thrombolytic efficacy.
The present study sought to assess the value of myoglobin,
cardiac troponin T and creatine kinase-MB fraction concen-
tration (CKMB mass) as predictors of failure of early restora-
tion of TIMI grade 3 flow in acute MI.
Methods
Patients. The patients involved were enrolled in two reper-
fusion studies that have been described elsewhere (23,24).
Patients who presented with typical ischemic chest pain
.20 min in duration and $1-mm ST segment elevation in two
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contiguous electrocardiographic (ECG) leads, were treated
with aspirin (300 to 325 mg) and 1.5 million U of streptokinase
by rapid infusion (over 30 to 60 min), followed by either
heparin or hirulog (as a bolus plus infusion).
Patients were considered current smokers if they smoked
tobacco regularly or had stopped smoking within the previous
6 months and were considered hypertensive if they were receiv-
ing antihypertensive medication at admission. Dyslipidemia was
defined as a fasting total serum cholesterol $5.2 mmol/liter.
Diabetic patients were those requiring treatment, with or
without insulin, for carbohydrate intolerance.
Biochemical markers. Blood samples for myocardial pro-
tein measurement were drawn immediately before starting the
streptokinase infusion and at 30, 60, 90 and 120 min after the
start of thrombolytic therapy. The status of the IRA was
assessed at 90 min by coronary arteriography, and coronary
flow was graded according to TIMI criteria (1) by consensus
between an experienced cardiologist and cardiac radiologist
who had no knowledge of the clinical state of the patient and
the results of the biochemical markers. Any disagreement was
resolved by consensus with a third observer. Angiographic
analyses were performed at two separate sites, both of which
are experienced angiographic core laboratories for multicenter
trials. Direct correlation of TIMI flow readings between the
two sites was not performed because most of the reported
variation between observers applies to TIMI grade 2 flow
rather than TIMI grade 3 flow (25).
To determine whether cardiac catheterization could con-
tribute to an increase in the serum levels of the markers used,
particularly of myoglobin, a group of 19 patients undergoing
elective coronary angioplasty for nonoccluded vessels during
the same time period as the reperfusion studies were investi-
gated. No significant changes in the serum levels of any of the
markers occurred after arterial puncture and routine coronary
angioplasty (sampling performed at 30, 60 and 120 min after
arterial puncture).
Biochemical analysis. CKMB concentration (CKMB
mass) was assayed by the Stratus II immunoassay (Baxter);
myoglobin was measured with either the Behring immunologic
technique on an Opus analyzer (PB Diagnostics) or the Baxter
Stratus II immunoassay. Cardiac troponin T was measured by
an enzyme-linked immunoassay using Boehringer Mannheim
reagents (Mannheim, Germany) on a Boehringer ES 300
analyzer. The normal values for these proteins in our labora-
tories are CKMB mass #5 ng/ml; troponin T #0.1 ng/ml;
myoglobin #110 ng/ml.
Data analysis. Results are expressed as mean value 6 SD
where appropriate or as median (interquartile range) for data
not normally distributed. The concentrations of the marker
proteins obtained after the administration of streptokinase
were converted to ratios by dividing by the pretreatment value.
The 60- and 90-min ratios were examined for their ability to
discriminate between patients with TIMI grade 3 flow and
those with lower TIMI flow grades in the IRA at the 90-min
angiogram. Receiver operator characteristic (ROC) curves
were constructed for the sensitivities and specificities of the
ratios for the detection of TIMI grade 0 to 2 flow at 60 and
90 min (Fig. 1) for ratios between 1.0 (i.e., no rise in concen-
tration of marker protein vs. baseline levels) and the ratio at
which the curve became asymptotic (i.e., no further increase in
sensitivity). The predictive values (positive and negative) were
Abbreviations and Acronyms
CKMB 5 creatine kinase-MB fraction
ECG 5 electrocardiogram, electrocardiographic
IRA 5 infarct-related artery
MI 5 myocardial infarction
ROC 5 receiver operating characteristic
TIMI 5 Thrombolysis in Myocardial Infarction
Figure 1. ROC curves representing the sensitivity and specificity of the
marker ratios at 60 (top) and 90 min (bottom) for the detection of
TIMI grade 0 to 2 flow in the IRA at the 90-min angiogram. For the
60-min curves, the data points represent ratios of 1.0, 1.5, 5.0, 6.0 and
15.0. For the 90-min curves, the data points represent ratios of 1.0, 2.0,
5.0, 10.0, 15.0 and 30.0. Circles 5 CKMB; squares 5 troponin T;
triangles 5 myoglobin.
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calculated for two ratios from the section of the ROC curve
with the best balance between sensitivity and specificity. The
same ratios were chosen for all three marker proteins because
their ROC curves were similar.
Statistical analyses were performed using SPSS for Win-
dows Version 6.1 running on a personal computer. Between-
group analyses were made using a Kruskall-Wallis H test (for
data not normally distributed) and where there was a statisti-
cally significant result (p , 0.05), post hoc comparisons
between individual groups were made using a Mann-Whitney
U test corrected for multiple comparisons by multiplying the p
value obtained by the number of comparisons made. This is a
rigorous and conservative method of correcting for multiple
comparisons in nonparametric analyses. Within-group com-
parisons for nonparametric data were made using a Friedman
two-way analysis of variance, and matched-pairs comparisons
were made using a Wilcoxon matched-pairs signed-rank test,
again corrected for multiple comparisons by multiplying the p
value obtained by the number of comparisons made. Nominal
data were evaluated using a chi-square test.
Results
Patients. The study included 105 patients (78% male;
mean age 59.1 6 10.4 years); their background characteristics
are summarized in Table 1. Treatment with intravenous strep-
tokinase was instituted within 4 h of the onset of chest pain in
73% of patients and within 3 h in 55%. TIMI grade 3 flow in
the IRA was seen in 59 patients (56%) at 90 min. Of the
remaining 46 patients, 20 had TIMI grade 0, 6 had TIMI grade
1, and 20 had TIMI grade 2 flow. TIMI grade 3 flow was seen
more often in current smokers than nonsmokers (p , 0.05)
and in patients presenting with their first myocardial infarction
(p , 0.05). However, patients with TIMI grade 3 flow were not
significantly different from the other patients with respect to
other major risk factors for coronary disease (history of
hypertension, dyslipidemia or diabetes). Sixty-eight percent of
patients with TIMI grade 3 flow presented within 3 h of
symptom onset, whereas only 40% of patients with lower flow
grades presented within 3 h (p , 0.01). On multivariate logistic
regression analysis of all the baseline variables, only time to
treatment (p 5 0.003) and gender (p 5 0.05) were independent
predictors of TIMI grade 3 flow in the IRA at 90 min.
The serum levels of the marker proteins measured before
streptokinase infusion were within the normal range for our
laboratories in most patients (CK activity 78%, CKMB mass
80%, troponin T 83%), apart from myoglobin concentration,
which was in the normal range in only 50%. For the 58 patients
(55%) who received streptokinase within 3 h of symptom
onset, serum levels were within the normal range for CK
activity in 91%, troponin T in 96%, CKMB mass in 95% and
myoglobin in 75%.
Serum levels of the myocardial proteins between 0 and
120 min after streptokinase administration are presented (me-
dian [25th, 75th percentiles]) in Table 2. The ratios of these
proteins at 30, 60, 90 and 120 min after the start of the
streptokinase infusion to the pretreatment values are shown in
Figure 2.
Results by TIMI flow grade. At 30 min there was minimal
elevation of CKMB mass and myoglobin concentrations in
patients with TIMI grade 3 flow in the IRA but no change in
troponin T. The concentrations of all three markers were
significantly raised by 60 and 90 min (Table 2, Fig. 2). The
median CKMB mass ratios at 60 and 90 min, respectively, were
5.6 and 10.0; those for troponin T were 3.0 and 14.7, respec-
tively, and those for myoglobin were 7.7 and 19.3, respectively
(p , 0.001 at 60 min and p , 0.0001 at 90 min vs. baseline). As
shown in Table 2 and Figure 2, CKMB mass and troponin T
levels were still rising rapidly 120 min after thrombolytic
therapy, but myoglobin levels were not significantly different
from those at 90 min.
In the patients with TIMI grade 0 to 2 flow at 90 min, the
myoglobin and CKMB mass ratios were 2.0 and 1.8, respec-
tively, at 60 min (both p , 0.002). The rise in troponin T
concentrations was less (median ratio 1.0, p , 0.01). The ratios
of all three markers were raised at 90 min (p , 0.0001 vs.
baseline), but the magnitude of the change was less in patients
with TIMI grade 0 to 2 flow than in patients with TIMI grade
3 flow: CKMB mass ratio 2.9, troponin T ratio 2.5 myoglobin
ratio 2.2. At 120 min, the ratios were CKMB mass 3.3 (p 5
0.003), troponin T 4.0 (p , 0.001) and myoglobin 2.9 (p ,
0.001) compared with 90 min.
Diagnosis of reperfusion. At 60 min after the start of
streptokinase infusion, the median marker ratios for patients
with TIMI grade 3 and TIMI grade 0 to 2 flow in the IRA were,
respectively, CKMB mass 5.6 and 2.0 (p 5 0.002); troponin T
3.0 and 1.0 (p , 0.005); and myoglobin 7.8 and 1.8 (p 5
Table 1. Clinical Data
All Patients
(n 5 105)
TIMI Flow Grade at
90 min
p
Value
3
(n 5 59)
,3
(n 5 46)
Age (yr) 59.1 6 10.4 56.3 6 9.2 62.8 6 10.7 0.001
Men 82 (78%) 50 (85%) 32 (70%) 0.06
Time to SK (min) 165 140 219 0.0004
(20,570) (20,550) (78,570)
Infarct site
Ant 31 18 13
Nonant 74 41 33
CK peak (IU/liter) 1,674 1,440 1,873
(92, 9,987) (92, 9,987) (251, 7,788)
Current smoker 48% 58% 37% ,0.05
Diabetes mellitus 17% 12% 24%
Dyslipidemia 58% 62% 58%
HTN 23% 24% 22%
Prev MI 12% 6.8% 20% ,0.05
Data presented are mean value 6 SD, median (25th, 75th percentiles) or
number (%) of patients. Ant 5 anterior; CK peak 5 peak value of creatine
kinase activity; HTN 5 hypertension; Nonant 5 nonanterior; Prev MI 5
previous myocardial infarction; Time to SK 5 time from onset of chest pain to
start of streptokinase infsuion; TIMI 5 Thrombolysis in Myocardial Infarction.
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0.0003). The median 90-min marker ratios for patients with
TIMI grade 3 and TIMI grade 0 to 2 flow in the IRA were,
respectively, CKMB mass 10.0 and 2.9; troponin T 14.7 and
2.5; and myoglobin 19.3 and 2.2. These differences were all
statistically significant (p , 0.0001). The power of these ratios
to discriminate between patients with TIMI grade 3 flow and
those with TIMI grade 0 to 2 flow, by the Mann-Whitney U
test, was high for all three markers (CKMB mass 0.9, troponin
T 0.7, myoglobin 0.9) regardless of the assumptions about the
distribution of values. There were no significant differences in
the ratios at 60 or 90 min between patients with TIMI grade 0
or 1 flow and those with TIMI grade 2 flow in the IRA at
90 min.
To determine the sensitivity and specificity of individual
markers for detecting TIMI flow grades ,3 at 60 and 90 min
after commencing streptokinase infusion, ROC curves were
constructed (Fig. 1). The sensitivities, specificities and positive
and negative predictive values for ratios of 1.5 and 5 at 60 min
and for ratios of 5 and 10 at 90 min are shown in Table 3. The
use of a ratio of 5 at 60 min and and a ratio of 10 at 90 min for
any of the three proteins was sensitive for the detection of
TIMI flow grades ,3, with the best negative predictive value
(94%) at both times provided by troponin T. These ratios
correspond to the section of the ROC curves showing the best
balance between sensitivity and specificity. The use of higher
ratios to triage patients for invasive investigation or other
therapies would therefore add little sensitivity and would
reduce the specificity, as illustrated in Figure 1.
To determine whether baseline differences, such as time to
treatment, between patients with TIMI grade 3 flow and those
with TIMI grade 0 to 2 flow might affect the ability of the ratios
at 60 and 90 min for predicting TIMI grade 0 to 2 flow, the
sensitivities of the ratios were assessed independently for early
(#3 h) versus late (.3 h) treatment, smoking habits, previous
myocardial infarction and gender. When all subgroups were
examined, the sensitivities for 60-min marker ratios of 5 for
detecting 90-min TIMI grade 0 to 2 flow ranged from 80% to
100% and those for 90-min ratios of 10 between 83% and
100%.
Discussion
Noninvasive prediction of failed reperfusion. In the pre-
thrombolytic era it was shown (26) that levels of biochemical
markers of myocardial necrosis in peripheral blood remained
essentially normal for several hours after acute myocardial
infarction. In the present study, the levels of myocardial
proteins (CKMB mass, troponin T and myoglobin) were within
the normal range in most patients at the time of presentation.
The changes in serum concentration of these proteins after
intravenous streptokinase were examined as a noninvasive
indicator of failure to achieve TIMI grade 3 flow in the IRA.
The ideal noninvasive assessment of thrombolytic efficacy
would allow sufficient time for reperfusion to take place while
providing evidence of failure of reperfusion quickly enough for
other strategies to be used. We prospectively collected samplesTa
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at 30 min after the start of thrombolytic therapy to develop
noninvasive criteria for determining reperfusion, but assess-
ment at ;60 min is probably the earliest practical time to
evaluate incomplete reperfusion noninvasively. In the present
study, if the cardiac troponin T ratio was #5 at 60 min, then
failure of treatment to restore 90-min TIMI grade 3 flow was
identified with 97% sensitivity and 43% specificity. If the ratio
was #10 at 90 min, then TIMI flow grades ,3 were predicted
with 95% sensitivity and 58% specificity. The negative predic-
tive value was high in both cases (94%); thus, if the troponin T
ratio 60 min after the start of thrombolysis was .5 or .10 after
90 min, it was 94% certain that there was TIMI grade 3 flow in
the IRA.
Nevertheless, both myoglobin and CKMB mass ratios ap-
peared to have a sensitivity and specificity for the detection of
TIMI grade 0 to 2 flow similar to that of the troponin T ratio
(Table 3). A CKMB mass ratio of 10 at 90 min had a negative
predictive value of 87%, whereas a 90-min myoglobin ratio of
10 had a negative predictive value of 86%. As shown in Table
3, the sensitivities, specificities and positive and negative
predictive values at 60 min were similar to those at 90 min for
all three markers.
Implications for the triage of patients with myocardial
infarction. Myoglobin is probably the most sensitive available
marker of myocardial necrosis and may be the biochemical
marker of choice for the early diagnosis of myocardial infarc-
tion. It is released into the circulation early after myocyte
damage (16,18,20) but lacks tissue specificity (19). There is
rapid renal clearance of myoglobin (in the absence of renal
failure or low cardiac output) (27), which may limit its useful-
ness, especially in patients who present late. However, cardiac
Figure 2. Box plots of marker ratios (CKMB mass [top]; troponin T
[middle]; myoglobin [bottom]) at 30, 60, 90 and 120 min after the start
of streptokinase infusion, according to the TIMI flow grade in the IRA
on the 90-min angiogram. Upper and lower limits of the boxes represent
the 25th and 75th percentiles, with the median shown as a horizontal line
within the box; error bars are the 10th and 90th percentiles. #p 5 0.001,
##p 5 0.0003, †p , 0.005, ††p , 0.0001, TIMI grade 3 flow (hatched
boxes) versus lower TIMI flow grades (open boxes).
Table 3. Utility of 60- and 90-Minute Marker Ratios for Predicting
Failed Thrombolysis
Marker Ratio Sens (%) Spec (%) PPV (%) NPV (%)
60 min
CKMB mass
1.5 33 85 75 49
5 93 60 76 86
Troponin T
1.5 70 65 67 69
5 97 43 63 94
Myoglobin
1.5 42 89 79 62
5 92 59 69 89
90 min
CKMB mass
5 82 66 67 82
10 91 49 61 87
Troponin T
5 82 67 68 88
10 95 58 65 94
Myoglobin
5 84 73 73 84
10 88 65 69 86
CKMB 5 creatine kinase, MB fraction; NPV 5 negative predictive value;
PPV 5 positive predictive value; Sens 5 sensitivity; Spec 5 specificity.
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troponin T is highly specific for myocardium and demonstrates
a pattern of early but sustained release after myocyte damage
(28). Although troponin T has greater tissue specificity than
the other markers studied, our results imply that a system of
triage for patients with MI treated with intravenous thrombo-
lytic therapy could be based on any one of the three.
If a triage system were based on a 60-min marker ratio #5
to identify patients likely to have 90-min TIMI grade flow ,3
in the IRA, it would identify nearly all patients with “failure of
reperfusion.” Because all three proteins can now be analyzed
with a laboratory turnaround time of ,15 min, any one of the
three could be useful for the identification of patients who
might benefit from other procedures, such as cardiac catheter-
ization with a view to rescue coronary angioplasty. If this
strategy were adopted, the positive predictive value of 63% to
76% for a ratio of 5 means that a small proportion of patients
would have TIMI grade 3 flow in the IRA at 90 min, and may
undergo catheterization unnecessarily.
Incomplete reperfusion. Patients who have TIMI grade 2
flow in the IRA after thrombolysis have a poorer outcome than
those with TIMI grade 3 flow (2,29), although it is not yet clear
whether TIMI grade 2 flow is the cause of a poorer outcome or
merely a marker of increased risk for adverse events (30). The
Second Thrombolytic Trial of Eminase (Anistreplase) in Acute
Myocardial Infarction (TEAM-2) (31) and third TEAM
(TEAM-3) (32) studies also showed a difference in the kinetics
of the biochemical markers of myocardial infarction, with more
rapid enzyme release and smaller enzyme peaks (probably
indicating less myocardial necrosis) in patients with TIMI
grade 3 flow than in those with TIMI grade 2 flow. Analysis of
the 20 patients in the present series with TIMI grade 2 flow
supports the concept that TIMI grade 2 flow represents a
“mostly occluded artery” because in these 20 patients the
CKMB mass ratio at 90 min was ,10 in 85%, the troponin T
ratio was ,10 in 89%, and the myoglobin ratio was ,10 in
81%.
Comparison with other studies. Our data are consistent
both with the earlier reperfusion studies using time-activity
curves of traditional markers (7–15) and with newer studies
based on the release patterns of myoglobin and cardiac
troponin T. Zabel et al. (20) concluded that the slope of the
change in serum marker concentration within the first 90 min
after thrombolysis was a sensitive and specific measurement of
thrombolytic success and that myoglobin was the most useful
marker because of its early rise. They did not find troponin T
analysis to be any more useful than analysis of CK or CKMB
activity. However, in a small Japanese study (33), a significant
increase in troponin T level was seen 60 min after reperfusion
with either intracoronary thrombolysis or angioplasty. We also
found that the troponin T ratio had begun to rise abruptly by
60 min, although the changes were more definite by 90 min.
The Prospective Evaluation of Reperfusion Markers (PERM)
group (34) found that the relative increase in marker levels,
particularly for myoglobin, troponin T and CK-MM3/CK-
MM1 isoforms, as a better predictor of IRA patency than were
the slopes of the changes. Those investigators found (34) that
the relative increase of any one of their three markers above a
certain threshold could be used as a noninvasive diagnostic test
for patency of the IRA, but they judged that of the three,
myoglobin was probably the marker of choice.
Limitations of the study. The TIMI flow and the marker
concentration data reported here are from two different insti-
tutions and were not directly compared. Each patient acted as
his or her own control in the calculation of the marker ratios,
so this approach is not likely to have introduced an error at
that level. Threshold marker ratios to determine TIMI grade 0
to 2 flow, especially at 60 min, may be further defined by
construction of ROC curves from a larger study sample.
There may have been a discrepancy between the two
angiographic core laboratories with respect to TIMI flow
grading. The TIMI flow classification has proved useful both in
research and in clinical practice but is a subjective index, and
considerable interobserver variation in flow grading between
local and core laboratory assessment has been shown (25). This
variation is seen most often with TIMI grade 2 flow and rarely
with TIMI grade 3 flow, so we consider any error introduced in
this way to be small.
Conclusions. The present study showed that after throm-
bolytic therapy for acute myocardial infarction, the ratios of
the serum levels of myocardial proteins at 60 and 90 min to
prethrombolytic values can be used to predict which patients
will not have TIMI grade 3 flow in the IRA at 90 min. The
method allows simple, rapid and reliable diagnosis of TIMI
flow grades ,3 with no need for the construction of complex
time–activity curves for the various marker proteins or correc-
tion for the concentration of the marker at the time of
presentation. The index appears to be independent of the site
and extent of infarction, the duration of symptoms before the
start of thrombolytic therapy, the gender of the patient and the
history of previous infarction. Although the present study was
performed with the “traditional” laboratory-based assays, all
three proteins can now be assayed rapidly (within 15 min),
allowing an answer to be obtained quickly at the bedside
(33,35). Our results also provide the basis for a prospective
study to determine whether patients with apparent failure of
reperfusion after intravenous thrombolytic therapy, based on
noninvasive testing, would benefit from other therapies.
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